Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel

Autor:	Arrieta, Oscar, Anaya, Pablo, Morales-Oyarvide, Vicente, Ramírez-Tirado, Laura Alejandra, Polanco, Ana C.
Zdroj:	The European Journal of Health Economics, 2016 Sep 01. 17(7), 855-863.
Databáze:	JSTOR Journals
Externí odkaz:	https://www.jstor.org/stable/24774210 Zobrazit plný text záznamu Full text from SpringerLink